The Mounjaro Experience, Designed For Patients Like Julia1
Unhappy with her A1C and weight, concerned about life with T2D*
- Recently diagnosed with T2D
- Not to her A1C goal on metformin
- With her T2D, she struggles with her weight despite her efforts with diet and exercise
An elevated A1C and excess weight contribute to the burden of T2D2-4
Get patients started on Mounjaro
Start your patients with a sample (2.5 mg) and a prescription (5 mg)
Provide patients a 1-month† sample of Mounjaro 2.5 mg
Samples include 4 once-weekly pens and information about the Mounjaro Savings Program.
See Savings Card Terms and Conditions.
Starting and continuing once-weekly Mounjaro‡
- Initiate with the 2.5-mg dose
- After 4 weeks on the 2.5-mg dose, increase to the 5-mg dose
If additional glycemic control is needed, you can continue to increase the dose by 2.5-mg increments after at least 4 weeks on the current dose. The maximum dose is 15 mg once weekly.
More doses to help achieve individual glycemic goals1
- A single-use, once-weekly, auto-injection pen with a hidden needle
- Available in 6 doses: a 2.5-mg starting dose and 5-mg, 7.5-mg, 10-mg, 12.5-mg, and 15-mg doses
1-MONTH SUPPLY (28 DAYS)
3-MONTH SUPPLY (84 DAYS)
Storing and dispensing the Mounjaro pen1
Store Mounjaro in a refrigerator at 36°F to 46°F (2°C to 8°C)
- If needed, each single-dose pen can be stored unrefrigerated at temperatures not to exceed 86°F (30°C) for up to 21 days
- Do not freeze Mounjaro. Do not use Mounjaro if frozen
- Store Mounjaro in the original carton to protect from light
Getting patients started1
As you get your patients started on Mounjaro, here is some information that may help the conversation.
It's taken once weekly1
It's in a single-dose pen with a no-see needle2
It helps control blood sugar1
- Mounjaro can help lower A1C and blood glucose levels
- In clinical trials, average A1C reductions ranged from 1.8% to 2.1% for the 5-mg dose, 1.7% to 2.4% for the 10-mg dose, and 1.7% to 2.4% for the 15-mg dose
Select Important Safety Information
Risk of Thyroid C-cell Tumors: Counsel patients regarding the potential risk for MTC with the use of Mounjaro and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Mounjaro. Such monitoring may increase the risk of unnecessary procedures, due to the low test specificity for serum calcitonin and a high background incidence of thyroid disease. Significantly elevated serum calcitonin values may indicate MTC and patients with MTC usually have calcitonin values >50 ng/L. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated.